Presumptive implications of epidermal growth factors in inflammation

Héctor José Pérez Hernández

Presumptive implications of epidermal growth factors in inflammation

Héctor José Pérez Hernández

Texto completo:

PDF (English)

Resumen

Epidermal Growth Factor is a protein of only 53 amino acids, with considerable thermodynamic stability, provided by its three desulfide bridges. It has structural homology with a wide series of growth factors, distinguishing its typical motif from this family of proteins. The known function of this molecule is closely related to the heterodimerization of ErbB1 and its activation with implications in cell metabolism and cell division. Although the role of EGFR is well documented in the inflammatory context, information regarding the participation of its ligand is scarce. Evidence suggests that this molecule could be a promising marker of inflammation. A better understanding of the role of EGF in inflammation opens new therapeutic opportunities in the Cuban scenario based on the positioning of CIMAvax-EGF, a serum EGF depletion therapy with consolidated safety.

Palabras clave

serum biomarkers/inflammation; epidermal growth factor; CIMAvax-EGF

Referencias

Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem [Internet]. 1987 [cited 2023 Nov 30];56(1):881–914. Available from: https://pubmed.ncbi.nlm.nih.gov/3039909/

Shakhakarmi K, Seo JE, Lamichhane S, Thapa C, Lee S. EGF, a veteran of wound healing: highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies. Arch Pharm Res [Internet]. 2023 [cited 2023 Nov 30];46(4):299–322. Available from: https://pubmed.ncbi.nlm.nih.gov/36928481/

Gray A, Dull TJ, Ullrich A. Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor. Nature [Internet]. 1983 [cited 2023 Nov 30];303(5919):722–5. Available from: https://pubmed.ncbi.nlm.nih.gov/6304537/

Bell GI, Fong NM, Stempien MM, Wormsted MA, Caput D, Ku L, et al. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res [Internet]. 1986 [cited 2023 Nov 30];14(21):8427–46. Available from: https://pubmed.ncbi.nlm.nih.gov/3491360/

Scott J, Patterson S, Rall L, Bell GI, Crawford R, Penschow J, et al. The structure and biosynthesis of epidermal growth factor precursor. J Cell Sci [Internet]. 1985 [cited 2023 Nov 30];1985(Supplement_3):19–28. Available from: https://pubmed.ncbi.nlm.nih.gov/3011823/

Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res [Internet]. 2017 [cited 2023 Nov 30];143:142–50. Available from: http://dx.doi.org/10.1016/j.antiviral.2017.03.022

Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res [Internet]. 2019 [cited 2023 Nov 30];139:395–411. Available from: https://pubmed.ncbi.nlm.nih.gov/30500458/

Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10aed. Madrid: Elsevier; 2021.

Yoo J, Perez CER, Nie W, Edwards RA, Sinnett-Smith J, Rozengurt E. TNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol [Internet]. 2012 [cited 2023 Nov 30];302(8):G805–14. Available from: https://pubmed.ncbi.nlm.nih.gov/22301110/

Yoo J, Rodriguez Perez CE, Nie W, Sinnett-Smith J, Rozengurt E. TNF-α and LPA promote synergistic expression of COX-2 in human colonic myofibroblasts: role of LPA-mediated transactivation of upregulated EGFR. BMC Gastroenterol [Internet]. 2013 [cited 2023 Nov 30];13(1). Available from: https://pubmed.ncbi.nlm.nih.gov/23688423/

Zhuang S, Liu N. EGFR signaling in renal fibrosis. Kidney Int Suppl (2011) [Internet]. 2014 [cited 2023 Nov 30];4(1):70–4. Available from: https://pubmed.ncbi.nlm.nih.gov/26312153/

Upagupta C, Shimbori C, Alsilmi R, Kolb M. Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev [Internet]. 2018 [cited 2023 Nov 30];27(148):180033. Available from: https://pubmed.ncbi.nlm.nih.gov/29950306/

Kalinina O, Golovkin A, Zaikova E, Aquino A, Bezrukikh V, Melnik O, et al. Cytokine storm signature in patients with moderate and severe COVID-19. Int J Mol Sci [Internet]. 2022 [cited 2023 Nov 30];23(16):8879. Available from: https://pubmed.ncbi.nlm.nih.gov/36012146/

Ahern DJ, Ai Z, Ainsworth M, Allan C, Allcock A, Angus B, et al. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell [Internet]. 2022 [cited 2023 Nov 30];185(5):916-938.e58. Available from: https://pubmed.ncbi.nlm.nih.gov/35216673/

Schumacher N, Rose-John S. ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer. Biochim Biophys Acta Mol Cell Res [Internet]. 2022 [cited 2023 Nov 30];1869(1):119141. Available from: https://pubmed.ncbi.nlm.nih.gov/34610348/

Monserrat J, Gómez-Lahoz A, Ortega M, Sanz J, Muñoz B, Arévalo-Serrano J, et al. Role of innate and adaptive cytokines in the survival of COVID-19 patients. Int J Mol Sci [Internet]. 2022 [cited 2023 Nov 30];23(18):10344. Available from: https://pubmed.ncbi.nlm.nih.gov/36142255/

Dülger SU, Mutlu N, Ceylan İ, Özhan E. The relationship between lung fibrosis, the epidermal growth factor receptor, and disease outcomes in COVID-19 pneumonia: a postmortem evaluation. Clin Exp Med [Internet]. 2022;23(4):1181–8. Available from: http://dx.doi.org/10.1007/s10238-022-00872-7

Popa X, García B, Fuentes KP, Huerta V, Alvarez K, Viada CE, et al. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. Oncoimmunology [Internet]. 2020 [cited 2023 Nov 30];9(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32923124/

Crombet Ramos T, Santos Morales O, Dy GK, León Monzón K, Lage Dávila A. The position of EGF deprivation in the management of advanced non-small cell lung cancer. Front Oncol [Internet]. 2021 [cited 2023 Nov 30];11. Available from:https://pubmed.ncbi.nlm.nih.gov/34211836/

RPCEC [Internet]. Havana: Work Team of the Cuban Public Registry of Clinical Trials, National Coordinating Center for Clinical Trials - MINSAP. CIMAvax-EGF®-convalescents with post-COVID-19 respiratory disorders-adults-Phase II (CORVAXCIM); 2021 Dec 06 [cited 2021 Dec 13]; [7 screens]. Available from: https://www.rpcec.sld.cu/ensayos/RPCEC00000375-Sp

Enlaces refback

No hay ningún enlace refback.

Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.